Reducing the Native Tropism of Adenovirus Vectors Requires Removal of both CAR and Integrin Interactions

ABSTRACT The development of tissue-selective virus-based vectors requires a better understanding of the role of receptors in gene transfer in vivo, both to rid the vectors of their native tropism and to introduce new specificity. CAR and αv integrins have been identified as the primary cell surface components that interact with adenovirus type 5 (Ad5)-based vectors during in vitro transduction. We have constructed a set of four vectors, which individually retain the wild-type cell interactions, lack CAR binding, lack αv integrin binding, or lack both CAR and αv integrin binding. These vectors have been used to examine the roles of CAR and αv integrin in determining the tropism of Ad vectors in a mouse model following intrajugular or intramuscular injection. CAR was found to play a significant role in liver transduction. The absence of CAR binding alone, however, had little effect on the low level of expression from Ad in other tissues. Binding of αv integrins appeared to have more influence than did binding of CAR in promoting the expression in these tissues and was also found to be important in liver transduction by Ad vectors. An effect of the penton base modification was a reduction in the number of vector genomes that could be detected in several tissues. In the liver, where CAR binding is important, combining defects in CAR and αv integrin binding was essential to effectively reduce the high level of expression from Ad vectors. While there may be differences in Ad vector tropism among species, our results indicate that both CAR and αv integrins can impact vector distribution in vivo. Disruption of both CAR and αv integrin interactions may be critical for effectively reducing native tropism and enhancing the efficacy of specific targeting ligands in redirecting Ad vectors to target tissues.

[1]  S. Fawell,et al.  Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  D. Curiel,et al.  A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  R. Alemany,et al.  Blood clearance rates of adenovirus type 5 in mice. , 2000, The Journal of general virology.

[4]  M. Weitzman,et al.  Molecular adaptors for vascular-targeted adenoviral gene delivery. , 2000, Human gene therapy.

[5]  M. Perricaudet,et al.  Highly efficient adenovirus-mediated gene transfer to cardiac myocytes after single-pass coronary delivery. , 2000, Human gene therapy.

[6]  J. Nalbantoglu,et al.  Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route. , 2000, Human gene therapy.

[7]  P. Ray,et al.  Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. , 2000, Human gene therapy.

[8]  B. Davidson,et al.  Increasing epithelial junction permeability enhances gene transfer to airway epithelia In vivo. , 2000, American journal of respiratory cell and molecular biology.

[9]  I. Kovesdi,et al.  Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. , 1999, Science.

[10]  D. Brough,et al.  Construction of a Pseudoreceptor That Mediates Transduction by Adenoviruses Expressing a Ligand in Fiber or Penton Base , 1999, Journal of Virology.

[11]  A. Houtsmuller,et al.  Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers , 1999, Gene Therapy.

[12]  P. Stewart,et al.  Role of αv Integrins in Adenovirus Cell Entry and Gene Delivery , 1999, Microbiology and Molecular Biology Reviews.

[13]  R. Pasqualini.  Vascular targeting with phage peptide libraries. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[14]  D. Curiel,et al.  Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. , 1999, Cancer research.

[15]  M. Welsh,et al.  Basolateral Localization of Fiber Receptors Limits Adenovirus Infection from the Apical Surface of Airway Epithelia* , 1999, The Journal of Biological Chemistry.

[16]  P. Stewart,et al.  Role of alpha(v) integrins in adenovirus cell entry and gene delivery. , 1999, Microbiology and molecular biology reviews : MMBR.

[17]  R. Dummer,et al.  The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. , 1998, Human gene therapy.

[18]  S. Hunger,et al.  Adenoviral-mediated gene transfer in lymphocytes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Brough,et al.  The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F , 1998, Journal of Virology.

[20]  S. Randell,et al.  Limited Entry of Adenovirus Vectors into Well-Differentiated Airway Epithelium Is Responsible for Inefficient Gene Transfer , 1998, Journal of Virology.

[21]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[22]  J. Bergelson,et al.  The Murine CAR Homolog Is a Receptor for Coxsackie B Viruses and Adenoviruses , 1998, Journal of Virology.

[23]  K. Zinn,et al.  Imaging and tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5) , 1998, Gene Therapy.

[24]  D. Brough,et al.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins , 1997, Journal of virology.

[25]  M. Kay,et al.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors , 1997, Journal of virology.

[26]  J. Zabner,et al.  Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. , 1997, The Journal of clinical investigation.

[27]  L. Philipson,et al.  HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Harvey,et al.  Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ , 1997, Journal of virology.

[29]  R. Crystal,et al.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. , 1997, Human gene therapy.

[30]  I. Kovesdi,et al.  Comparative analysis of adenovirus fiber-cell interaction: adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment , 1996, Journal of virology.

[31]  J. Wilson,et al.  Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithelia: implications for gene therapy of cystic fibrosis. , 1996, Gene therapy.

[32]  I. Kovesdi,et al.  Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. , 1995, Gene therapy.

[33]  B. Harfe,et al.  Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells , 1993, Journal of virology.

[34]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.